Inhibrx Biosciences (INBX) Operating Leases (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Operating Leases data on file, last reported at $4.1 million in Q4 2025.

• On a quarterly basis, Operating Leases fell 48.72% year-over-year to $4.1 million in Q4 2025; TTM through Dec 2025 was $4.1 million, a 48.72% decrease from a year earlier, with the FY2025 full-year figure at $4.1 million, down 48.72% from the prior year.
• Operating Leases for Q4 2025 stood at $4.1 million, down from $7.0 million in the prior quarter.
• Over the last five years, Operating Leases for INBX reached as high as $8.0 million in Q4 2024 and fell as low as $1.1 million in Q4 2023.
• Historically, Operating Leases has averaged $4.7 million across 3 years, with a median of $5.0 million in 2025.
• Across the five-year window, Operating Leases jumped 625.05% in 2024 and tumbled 48.72% in 2025, its largest moves.
• Year by year, Operating Leases stood at $1.1 million in 2023, then soared by 625.05% to $8.0 million in 2024, then sank by 48.72% to $4.1 million in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $4.1 million in Q4 2025, $7.0 million in Q3 2025, and $7.5 million in Q2 2025.